Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + temozolomide
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Local
01
Overview
A combination of two chemotherapeutic agents - doxorubicin, an anthracycline antibiotic, and temozolomide, an alkylating agent capable of crossing the blood-brain barrier. This combination has demonstrated synergistic effects in inhibiting cancer cells, particularly in glioblastoma multiforme (GBM), including temozolomide-resistant cells. The combination enhances doxorubicin uptake and induces higher apoptosis rates. Researchers have also developed conjugated compounds coupling these drugs via an acylhydrazone linkage as potential prodrugs for GBM treatment.
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on doxorubicin + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + temozolomide.